REALE, MARIA LUCIA
 Distribuzione geografica
Continente #
NA - Nord America 1.500
EU - Europa 863
AS - Asia 635
SA - Sud America 18
OC - Oceania 14
AF - Africa 13
Totale 3.043
Nazione #
US - Stati Uniti d'America 1.467
IT - Italia 312
SG - Singapore 215
CN - Cina 186
IE - Irlanda 135
SE - Svezia 116
GB - Regno Unito 68
DE - Germania 53
VN - Vietnam 53
UA - Ucraina 33
CA - Canada 29
JP - Giappone 29
HK - Hong Kong 27
FR - Francia 26
ID - Indonesia 26
IN - India 21
BE - Belgio 20
PL - Polonia 18
KR - Corea 15
AU - Australia 13
ES - Italia 13
JO - Giordania 12
FI - Finlandia 10
IR - Iran 10
TW - Taiwan 10
NL - Olanda 9
AT - Austria 8
TR - Turchia 8
CH - Svizzera 7
PK - Pakistan 7
RU - Federazione Russa 7
BR - Brasile 5
GR - Grecia 5
HR - Croazia 5
MA - Marocco 5
PE - Perù 5
CO - Colombia 4
EG - Egitto 4
LT - Lituania 4
RO - Romania 4
EC - Ecuador 3
PS - Palestinian Territory 3
TN - Tunisia 3
CZ - Repubblica Ceca 2
DK - Danimarca 2
MK - Macedonia 2
MX - Messico 2
MY - Malesia 2
NO - Norvegia 2
PA - Panama 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
BG - Bulgaria 1
IL - Israele 1
LK - Sri Lanka 1
MO - Macao, regione amministrativa speciale della Cina 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PH - Filippine 1
RS - Serbia 1
Totale 3.043
Città #
Chandler 237
Singapore 173
Santa Clara 153
Dublin 134
Fairfield 100
Turin 70
Nyköping 66
Ashburn 57
Woodbridge 49
Torino 43
Medford 37
Seattle 36
Beijing 35
Wilmington 35
Cambridge 34
Columbus 34
Houston 33
Princeton 30
Redwood City 28
Munich 26
Dong Ket 25
Jakarta 25
Ann Arbor 23
Hangzhou 22
New York 20
Central 17
Milan 17
Fremont 15
Guangzhou 15
Dearborn 13
Jacksonville 13
Amman 12
Brussels 12
Pisa 12
Seoul 12
Hebei 10
Nanjing 10
San Diego 10
Boston 9
London 9
Tokyo 9
Helsinki 8
Piemonte 8
Rome 8
Vienna 8
Warsaw 8
Chengdu 7
Montreal 7
Boardman 6
Karachi 6
Kraków 6
Los Angeles 6
Taipei 6
Toronto 6
Frankfurt am Main 5
Hefei 5
Jinan 5
Manchester 5
Shanghai 5
Shijiazhuang 5
Bologna 4
Castellaneta 4
Central District 4
Dalmine 4
Kingston upon Thames 4
Medellín 4
Naples 4
Ottawa 4
Paris 4
Preston 4
Pune 4
San Jose 4
Taichung 4
Tehran 4
Vancouver 4
Washington 4
Wuxi 4
Adana 3
Agadir 3
Amsterdam 3
Biella 3
Delhi 3
Falls Church 3
Florence 3
Genoa 3
Harbin 3
Hoffman 3
Istanbul 3
Kanata 3
Kulmbach 3
Mumbai 3
Namur 3
Norwalk 3
Parma 3
Ramallah 3
Redmond 3
River Edge 3
Rochester 3
San Francisco 3
Thai Nguyen 3
Totale 1.977
Nome #
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 241
Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018 193
Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review 170
Deficiencies in health-related quality of life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 168
Quality of life in patients with lung cancer: the way forward 139
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival 115
SELECTing adjuvant treatment in early stage epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer 114
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 114
SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit 104
Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018 103
Osimertinib-induced Cardiac Dysfunction in EGFRMutated Lung Cancer: A Case Series of Five Patients 99
LATITUDE and other coordinates in quality of life of prostate cancer patients 94
Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave 89
Clinical and molecular features of epidermal growth factor receptor (Egfr) mutation positive non‐small‐cell lung cancer (nsclc) patients treated with tyrosine kinase inhibitors (tkis): Predictive and prognostic role of co‐mutations 87
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era 85
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon? 82
Dealing with NSCLC EGFR mutation testing and treatment: a comprehensive review with an Italian real-world perspective 75
Repositioning PARP inhibitors in the treatment of thoracic malignancies 74
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients 72
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics 71
68 Ga-PSMA Uptake in Fibrous Dysplasia 70
Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018 69
Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: Are we actually ready? 65
Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features 65
Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements 65
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon 62
An examination of two dichotomies: Women with lung cancer and living with lung cancer as a chronic disease 61
Oncological Procedures and Risk Assessment of COVID-19 in Thoracic Cancer Patients: A Picture From an Italian Cancer Center 60
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer 59
Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review 57
Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center 50
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 49
Resistance to anaplastic lymphoma kinase inhibitors: Knowing the enemy is half the battle won 42
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program 28
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database 23
The KEY for chemo-immunotherapy combination: Taking NOTEs from squamous cell lung cancer 9
Totale 3.123
Categoria #
all - tutte 11.262
article - articoli 0
book - libri 0
conference - conferenze 307
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.569


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020147 0 0 0 0 0 20 23 18 28 22 20 16
2020/2021434 17 16 26 22 33 21 22 32 59 51 33 102
2021/2022605 46 33 37 27 36 28 41 40 21 66 144 86
2022/2023814 66 103 38 79 66 173 47 66 68 21 56 31
2023/2024437 69 58 20 54 17 48 8 25 10 40 50 38
2024/2025591 22 71 70 100 250 78 0 0 0 0 0 0
Totale 3.123